BioMarin Pharma (BMRN) Tops Q2 EPS by 31c, Offers Guidance

BioMarin Pharma (NASDAQ: BMRN) reported Q2 EPS of $0.54, $0.31 better than the analyst estimate of $0.23. Revenue for the quarter came in at $595.3 million versus the consensus estimate of $595.22 million.

GUIDANCE:

BioMarin Pharma sees FY2023 EPS of $1.80-$2.05, versus the consensus of $1.02. BioMarin Pharma sees FY2023 revenue of $2.375-2.5 million, versus the consensus of $2.46 million.

For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.

You May Also Be Interested In

• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• Piper Sandler on Fervo Energy (FRVO): 'Capital Access Supports Potential Upside'
• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI